Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 4/20 | 0.76 |
| ▸ | POLA1 | P09884 | 1/20 | 0.76 |
| ▸ | VDR | P11473 | 3/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | INPP5D | Q92835 | 1/20 | 0.62 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.61 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10024731 | 0.98 | CDC25A (0.79) | CDC25APOLA1VDRUSP2CYP2D6 | |
| SCHEMBL28835545 | 0.98 | CDC25A (0.79) | CDC25APOLA1VDRUSP2CYP2D6 | |
| SCHEMBL14365868 | 0.98 | CDC25A (0.79) | CDC25APOLA1VDRUSP2CYP2D6 | |
| SCHEMBL12205280 | 0.90 | VDR (0.79) | CDC25APOLA1VDRUSP2CYP2D6 | |
| SCHEMBL10052613 | 0.90 | VDR (0.79) | CDC25APOLA1VDRUSP2CYP2D6 | |
| SCHEMBL24403430 | 0.90 | VDR (0.79) | CDC25APOLA1VDRUSP2CYP2D6 | |
| SCHEMBL4739362 | 0.90 | VDR (0.79) | CDC25APOLA1VDRUSP2CYP2D6 | |
| SCHEMBL4739364 | 0.90 | VDR (0.79) | CDC25APOLA1VDRUSP2CYP2D6 | |
| SCHEMBL11371121 | 0.90 | VDR (0.79) | CDC25APOLA1VDRUSP2CYP2D6 | |
| SCHEMBL15372968 | 0.90 | VDR (0.79) | CDC25APOLA1VDRUSP2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6569411-B2 | Deodoring, microbiocides, marking odors | THE GILLETTE COMPANY | 2003-05-27 | — | — | US | disclosed |
| US-20030018055-A1 | Serine carbonates | FRATER GEORGE (CH) | 2003-01-23 | — | — | US | disclosed |
| EP-1008587-A1 | Serine carbonates | Givaudan Roure (International) S.A. (CH) | 2000-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018055-A1 | Serine carbonates | SRR, ME1, TASP1 | CDC25A 1103/4885POLA1 2639/4885VDR 1836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.